Navigation Links
Repligen Reports Positive Phase 2 Clinical Trial Results of,Secretin for MRI Imaging of the Pancreas

WALTHAM, Mass., May 10, 2007 /PRNewswire-FirstCall/ -- Repligen Corporation announced today positive results from a Phase 2 clinical trial to evaluate the use of RG1068, synthetic human secretin, as an agent to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). The study showed an improvement in sensitivity of detection of structural abnormalities of the pancreatic duct of approximately 20% with no loss in specificity, consistent with prior data and expectations. In addition, the study showed highly significant increases in the following three assessments: physician confidence in their ability to identify structural abnormalities, the number of pancreatic duct segments visualized and improvement in the overall quality of the MRI images. Detailed visual assessment of the pancreatic ducts and identification of structural abnormalities is important in the assessment, diagnosis and treatment of diseases such as acute and chronic pancreatitis.

This was a multi-center, baseline controlled, single dose study in which 80 patients with a history of pancreatitis received a secretin-enhanced MRI and an unenhanced MRI of the pancreas. All study operations and data analyses were conducted with protocols previously discussed with the U.S. Food and Drug Administration (FDA).

"We are pleased with the successful outcome of our first prospectively defined, blinded, multi-center clinical study to assess the use of secretin to aid in the detection of structural abnormalities of the pancreas," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen. "These quantitative results confirm what has previously been reported by physicians, and establishes a sound basis for discussions with the FDA regarding a clinical plan to receive marketing approval for secretin for MRI imaging of the pancreas. We believe there may be more than 100,000 potential MRI images of the
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... 04, 2015 Research ... addition of Jain PharmaBiotech,s new report "Animal ... their offering. This report describes and ... medicine and pharmaceuticals as well as improvement in ... in the application of biotechnology to manage genetic ...
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:8/4/2015)... ... 2015 , ... Worldwide Power Products acquires new assets, certifying ... in Texas. Effective July 1st of this year, Worldwide Power Products acquired operations ... the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 generators in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about ... Renew Man™ is standing up as a voice of authority for men seeking accurate ... aging industry with special experience and expertise in the safe and effective treatment of ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... “Dr. Google” before calling a physician. In an effort to share more and ... care provider in Pennsylvania to publicly share patient satisfaction ratings and comments about ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma researchers in Australia have ... may be a viable option. Surviving Mesothelioma has just posted an article on ... surgeons at the University of New South Wales, peritoneal mesothelioma patients ...
(Date:8/4/2015)... Las Vegas, Nevada (PRWEB) , ... August 04, ... ... INTIMATELY FEMALE, a striking contemporary look at unique artistic expressions from a diverse ... Motel inside the Life Is Beautiful Music & Art Festival on September 25-27, ...
Breaking Medicine News(10 mins):Health News:North Texas Acquisition Press Release 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4
... Net Hospital,Alliance of Florida launched its new Web ... Alliance and links to its member hospitals, as,well ... the 2008,session, and news clips and editorials on ... is designed as a resource for the,public, legislators ...
... program helps Alzheimer,s and dementia patients and ... families regain ... More than 5.2 million Americans,including 250,000 Ohioans, struggle with ... being unveiled in the greater,Cleveland area offers new hope ...
... University, ... University, CENTER VALLEY, Pa., March 24 ... in healthcare,life science and consumer electronics products, today ... Program: Tom Byers, Ph.D. and Tina,Seelig, Ph.D., Stanford ...
... 24 Isolagen(TM), Inc.,(AMEX: ILE ) today announced the ... net. $5.85 million of the sale amount was,paid at the ... next six weeks., "This is an important development for ... facility will enable us to further pursue the,implementation of our ...
... not getting needed screenings for breast and cervical tumors , , ... 32 studies suggests that obese women -- particularly white women ... breast and cervical cancer. , No one knows why ... or Pap smears. And it,s not known why obesity seems ...
... Drugstore Ltd. (NYSE: NPD ) ("China Nepstar" or ... the number of,directly operated stores, today announced that the ... ordinary share of US$0.06 per share, based,on its net ... is payable on,or around May 12th, 2008, to shareholders ...
Cached Medicine News:Health News:Cleveland Area Homewatch CareGivers Unveil New Alzheimer's Program 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 3Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 4Health News:Isolagen, Inc. Sells Switzerland Facility 2Health News:Isolagen, Inc. Sells Switzerland Facility 3Health News:Obese Women Less Likely to Be Tested for Some Cancers 2Health News:China Nepstar Chain Drugstore Announces Dividend 2Health News:China Nepstar Chain Drugstore Announces Dividend 3
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... peptic ulcers are caused by H. pylori ... while the patient is still present with ... of waived or non-waived laboratories.,The Right Choice ... rapid H. pylori test available; helps to ...
... CHECK 02 PLUS CONCENTRATOR ANALYZER Now there ... the operating parameters necessary for performing concentrator ... ™, an efficient and cost-effective analyzer designed ... concentration (%), flow rate (L-min), and patient ...
... Exclusively for the Japanese market:, ... advanced, low-sound level, low-power-consumption, high-performance oxygen ... settings., ,Offered in an attractive, ... was specifically designed to meet the ...
Medicine Products: